APYX — Apyx Medical Income Statement
0.000.00%
Last trade - 00:00- $153.51m
- $156.95m
- $52.84m
Annual income statement for Apyx Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 48.5 | 44.5 | 52.3 | 48.1 | 52.8 |
| Cost of Revenue | |||||
| Gross Profit | 33.6 | 29.1 | 33.8 | 29.4 | 33 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 63 | 68.1 | 72.7 | 66.9 | 59.3 |
| Operating Profit | -14.4 | -23.6 | -20.3 | -18.8 | -6.45 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.8 | -22.9 | -21.3 | -23.3 | -10.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.2 | -23.3 | -18.9 | -23.6 | -11.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -15.2 | -23.2 | -18.7 | -23.5 | -11.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.2 | -23.2 | -18.7 | -23.5 | -11.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.442 | -0.672 | -0.533 | -0.66 | -0.273 |